Dr. John Oates of Vanderbilt University was central in launching the field of clinical pharmacology and gave life to the concepts of first-pass drug metabolism and interindividual variation in the way humans process drugs. Dr. Oates also made seminal discoveries on the metabolism, biosynthesis, and pharmacology of eicosanoids. Watch the full interview for many more stories about testifying before Congress and Dr. Oates' love of sailing.
Dr. Christine Seidman of the Harvard Medical School has uncovered the genetic basis of many human cardiovascular disorders, from cardiomyopathy and heart failure to congenital heart malformations. In this interview, she speaks about her early intrigue with atrial natriuretic factor and her more current gene-intensive investigations. She also shares many more stories about her interest in the ear, an early inspirational patient, and her thoughts on work-life balance.
Professor Stephen O’Rahilly’s research has led to an increased understanding of the genetic causes of human obesity and insulin resistance. Using modern biochemical approaches and classical clinical observation in humans with profound metabolic disorders, O’Rahilly, from the Departments of Medicine and Clinical Biochemistry at the University of Cambridge, has shown that a person’s appetite and feeding behavior can be linked to specific genes. His work has challenged long-held dogmas and led to new treatment avenues. The full interview includes many more stories about how you can learn more from reading Chekhov than medical school and why he has stayed in Cambridge all these years.
More than almost any other scientist in the field of obesity and metabolism research, the work of Bruce Spiegelman, from the Dana-Farber Cancer Institute and Harvard Medical School, has informed potential targets for drug discovery that could burn fat and even turn fat into muscle. He was the first to suggest that inflammation underscores insulin resistance, and also the first to find the key regulator of adipogenesis, PPAR-γ.
If you, or someone you know, has Parkinson’s disease, mental health issues, or other neurological disorders, medication can often help. The bulk of these medications have been established based on the work of neuroscientist Paul Greengard from the Rockefeller University, who worked out just how the brain responds to neurotransmitters — the chemicals that help the brain signal. Most of what most neuroscientists know today about neurotransmission, and specifically the dynamics of slow synaptic transmission, is predicated on the work of Dr. Greengard. The interview features stories about his seminal research discoveries and his competitive streak in potato sack races.